About: ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand
Creator	Fontana, Donna Jemmerson, Ronald Schacker, Timothy Skogen, Aunica Tuite, Paul Weivoda, Starchild Andersen, John Dubinsky, Janet Schlievert, Patrick
Source	Elsevier; Medline; PMC
abstract	Abstract Leucine-rich alpha-2-glycoprotein-1 (LRG) is a serum glycoprotein of unknown function that has shown promise based on qualitative assessments as a biomarker for certain diseases including microbial infections and cancer. However, the lack of a quantitative assay for LRG has limited its application. Here an indirect enzyme-linked immunosorbent assay (ELISA) for quantifying LRG in human serum is described in which cytochrome c is employed as the capturing ligand and a monoclonal antibody specific for LRG is used to detect the captured glycoprotein. Application of this assay in quantifying LRG in various patients' sera is demonstrated. The concentration of LRG in sera of control subjects as determined by this assay is approximately 50 μg/ml. Consistent with expectations from published reports, LRG was found to be significantly elevated in the sera of some patients with a bacterial infection (toxic shock syndrome, TSS). LRG was only slightly elevated in patients infected with the human immunodeficiency virus as compared to uninfected control subjects, while normal levels of LRG were observed in patients with non-infectious diseases (inflammatory arthritis and neurological disorders, primarily Parkinson's disease). Although LRG and C-reactive protein (CRP) are both produced by the liver and are classified as acute-phase proteins, there was no significant correlation between the levels of LRG and CRP in the sera of the patients. Thus, LRG and CRP measurements are non-redundant and indicate different physiological contexts. The ELISA described in this report should be useful to further assess serum LRG as a biomarker for clinical diagnostics.
has issue date	2008-07-20(xsd:dateTime)
bibo:doi	10.1016/j.jim.2008.03.004
bibo:pmid	18436231
has license	els-covid
sha1sum (hex)	73ebfdd5f591df1bdf1734ab2a26f3461b87227f
schema:url	https://doi.org/10.1016/j.jim.2008.03.004
resource representing a document's title	ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand
has PubMed Central identifier	PMC7094546
has PubMed identifier	18436231
schema:publication	Journal of Immunological Methods
resource representing a document's body	covid:73ebfdd5f591df1bdf1734ab2a26f3461b87227f#body_text
is schema:about of	named entity 'application' named entity 'non-infectious diseases' named entity 'levels' named entity 'quantifying' named entity 'human' named entity 'demonstrated' named entity 'detect' named entity 'LRG' named entity 'assessments' named entity 'EXPECTATIONS' named entity 'COMPARED' named entity 'BACTERIAL INFECTION' named entity 'EMPLOYED' named entity 'LIMITED' named entity 'APPLICATION' named entity 'IS A' named entity 'NORMAL' named entity 'CRP' named entity 'HERE' named entity 'APPROXIMATELY' named entity 'PUBLISHED' named entity 'TSS' named entity 'FOUND' named entity 'TO DETECT' named entity 'SHOCK SYNDROME' named entity 'ASSESSMENTS' named entity 'GLYCOPROTEIN' named entity 'CONSISTENT WITH' named entity 'DIAGNOSTICS' named entity 'SERA' named entity 'SIGNIFICANT' named entity 'CLASSIFIED' named entity 'HUMAN IMMUNODEFICIENCY VIRUS' named entity 'DESCRIBED' named entity 'NON-' named entity 'ASSAY' named entity 'INDIRECT' named entity 'NEUROLOGICAL DISORDERS' named entity 'LIGAND' named entity 'QUANTITATIVE' named entity 'QUALITATIVE' named entity 'PHYSIOLOGICAL' named entity 'CANCER' named entity 'INCLUDING' named entity 'ARTHRITIS' named entity 'REDUNDANT' named entity 'SLIGHTLY' named entity 'HUMAN SERUM' named entity 'SPECIFIC' named entity 'CLINICAL' named entity 'MONOCLONAL ANTIBODY' named entity 'INFECTED' named entity 'PARKINSON' named entity 'SUBJECTS' named entity 'OBSERVED' named entity 'LRG' named entity 'CYTOCHROME C' named entity 'ELEVATED' named entity 'USED' named entity 'ACUTE-PHASE PROTEINS' named entity 'DIFFERENT' named entity 'LEVELS' named entity '27S' named entity 'DETERMINED BY' named entity 'ELISA' named entity 'LIVER' named entity 'BIOMARKER' named entity 'FUNCTION' named entity 'ENZYME-LINKED IMMUNOSORBENT ASSAY' named entity 'REPORTS' named entity 'C-REACTIVE PROTEIN' named entity 'CONTEXTS' named entity 'USEFUL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software